Secondary Logo

Journal Logo

Safety of High Dose Lidocaine in Flexible Bronchoscopy

Frey, William C. MD; Emmons, Ethan E. MD; Morris, Michael J. MD

doi: 10.1097/LBR.0b013e3181641b8e
Original Investigations
Free

Background The maximum safe dose for topical lidocaine during flexible bronchoscopy (FB) without toxicity is not established; recent guidelines advocate a dose <8.2 mg/kg. Noting our routine use of lidocaine above 12 mg/kg, we prospectively evaluated the safety of high dose topical lidocaine.

Methods The standard institution FB preparation included 4% nebulized lidocaine, 2% nasal viscous lidocaine, 2% aqueous lidocaine for the vocal cords, and 1% aqueous lidocaine for the tracheobronchial tree. Procedure data were collected to include FB indication and duration, lidocaine use, and postprocedure symptoms. Serum lidocaine and blood methemoglobin levels were obtained 45 minutes postlidocaine administration.

Results Consecutive data were collected for 154 patients with a mean age of 64.7 years. The most common FB indication (60%) was evaluation of a lung mass or mediastinal adenopathy. No arrhythmias or seizures were noted. Symptoms of euphoria or dizziness were reported in 84 patients (62.2%). Mean lidocaine usage was 15.4±4.5 mg/kg (1.17±0.20 gm). Lidocaine dose for females was significantly higher than males (16.9±4.9 mg/kg vs. 14.3±3.8 mg/kg, P=0.0003). There was no significant difference in dose on the basis of age, indication for FB, or presence of symptoms. Mean serum lidocaine level was 1.6±0.7 μg/mL and mean blood methemoglobin level was 0.7±0.3%. There were no significant differences shown.

Conclusions Our routine use of lidocaine in FB is higher than recommended. There were not significantly elevated serum lidocaine or blood methemoglobin levels, or clinical evidence of toxicity.

Pulmonary Disease/Critical Care Service, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, TX

No outside funding from any source was received during conduct of this research or preparation of this manuscript. All work done at Brooke Army Medical Center.

The opinions or assertions contained herein are the private views of the authors and are not to be construed as the reflecting the Department of the Army or the Department of Defense.

There is no conflict of interest.

Reprints: William C. Frey, MD, Pulmonary Disease/Critical Care (MCHE-MDP), 3851 Roger Brooke Drive, Brooke Army Medical Center, FT. Sam Houston, TX 78234-6200 (e-mail: william.frey@amedd.army.mil).

Received for publication October 10, 2007; accepted December 4, 2007

The maximum amount of topical lidocaine used for airway anesthesia to provide patient comfort during flexible bronchoscopy (FB) remains an ongoing question. An early survey of nearly 25,000 FBs noted 6 patients with complications (respiratory arrest, seizures) related to airway anesthesia and only 1 patient with methemoglobinemia.1 The National Institutes of Health (NIH) published guidelines in 1985 recommending a maximum cumulative lidocaine dose of 400 mg for asthmatics undergoing research FB, but subsequent guidelines published in 1991 only indicated minimizing the dose to avoid potential toxicity.2,3 Langmack et al4 conducted a definitive study in 2000 that demonstrated safety of lidocaine doses up to 8.2 mg/kg in an asthma population undergoing FB. In 2001, the British Thoracic Society (BTS) guidelines for routine FB recommended 8.2 mg/kg based primarily on this study.5 However, other studies demonstrated the safety of lidocaine in much higher doses.6–8 A small study of 19 elderly patients revealed no serious lidocaine toxicity or elevated serum levels greater than 5 μg/mL despite using a mean dose of 1200 mg (19 mg/kg) of topical lidocaine.6

A typical airway preparation for FB includes the application of 2% viscous lidocaine for the nasal mucosa, nebulized 4% topical lidocaine for oral inhalation, and 1% topical lidocaine for additional upper and lower airway mucosal anesthesia to control coughing. This airway preparation is approximately 500 mg of topical lidocaine. The amount of 1% lidocaine used is variable and physician dependent with approximately 100 mg used for direct application to the vocal cords and carina and additional lidocaine used for lower airway anesthesia to suppress coughing. Lidocaine is a very effective topical anesthetic with rapid mucosal absorption. Serious effects of lidocaine toxicity (seizures, methemoglobinemia, respiratory failure, and cardiac arrhythmias) are reported to begin at serum levels >5 μg/mL.9 Milder side effects such as drowsiness, dizziness, paresthesias, euphoria, nausea, and vomiting can occur at lower serum concentrations. Serum lidocaine clearance can be decreased in the elderly, patients with cardiac or liver disease, and those patients taking certain medications such as β-blockers, cimetidine, or verapamil.10

The experience with FB at our institution for the past 10 years has not demonstrated increased complications related to either lidocaine toxicity or methemoglobinemia despite an average topical lidocaine dose of 12 mg/kg given routinely. No large study has been conducted evaluating toxicity or methemoglobinemia related to high dose lidocaine in FB patients.

Back to Top | Article Outline

METHODS

Consecutive patients undergoing FB in the Pulmonary Clinic were recruited to participate in this study approved by the hospital Institutional Review Board. After obtaining informed consent, patients were given a handout during their nursing preprocedure assessment that explained the study protocol and asked about baseline symptoms. They were specifically asked not to discuss the handout questions with their pulmonologist who was blinded to the study procedure. Current medication use and past medical history were documented along with a baseline weight.

Standard operating procedure for our bronchoscopy suite included intravenous access with continuous heart rate, blood pressure, and pulse oximetry monitoring during the airway preparation and during the FB. A standard dose of 5 to 10 mL of 4% lidocaine was given via a hand-held nebulizer and 10 to 20 mL of 2% viscous lidocaine was inserted nasally. During this airway preparation, the bronchoscopy technician recorded the amount of 4% lidocaine used during the airway nebulization and the amount of 2% viscous lidocaine administered to anesthetize the nasal mucosa. All patients were given supplemental oxygen starting at 2L/min before the procedure to maintain oxygen saturations greater than 92%. Intravenous midazolam and fentanyl were given in incremental doses to achieve conscious sedation before insertion of bronchoscope and during the procedure. During the FB, 1% lidocaine was given as 5 mL aliquots routinely to anesthetize the vocal cords and carina. The technician recorded the amount of 1% lidocaine administered throughout the entire procedure as requested by the bronchoscopist. The bronchoscopist was not informed of the lidocaine amount used or asked to limit the amount during the procedure. All cardiac arrhythmias were recorded by nursing personnel per the conscious sedation guidelines and the total FB procedure time was documented. Serum lidocaine and blood methemoglobin (MetHb) levels were drawn 45 minutes after the last dose of lidocaine was administered. A repeat symptom questionnaire was completed at 2 hours postprocedure when the patient had adequately recovered from conscious sedation.

Serum concentration of lidocaine was analyzed on the COBAS INTEGRA 400 (Roche Diagnostics, Indianapolis, IN) using a fluorescence polarization assay containing an antilidocaine polyclonal antibody and a fluorescein-labeled lidocaine derivative. Serum concentrations were determined by measuring the differences between polarization of unbound and lidocaine-bound fluorescein. Serum MetHb concentrations were determined on the 800 Series Blood Gas Critical Analyte System (Ciba Corning Diagnostics, Norwood, MA) by spectrophotometric analysis of hemoglobin and its derivatives.

Comparison of mean values (age, lidocaine dose, lidocaine level, and MetHb level) by sex was performed using a Student paired t test. Comparison of mean values (age, lidocaine dose, lidocaine level, and MetHb level) by age group and indication was performed using a 1-way analysis of variance with a Bonferroni correction. P values less than 0.05 were considered significant. Analysis was performed on commercially available software (SPSS for Windows, version 11.5).

Back to Top | Article Outline

RESULTS

A total of 154 consecutive patients were enrolled in the protocol and completed the study procedures (no patients declined to participate in the study). There were 93 males (60%) and 61 females (40%) with a mean age of 64.3±13.7 years (range, 18 to 80 y). Indications for FB included evaluation of a pulmonary mass in 93 patients (60%), interstitial lung disease in 19 (12%), hemoptysis in 17 (11%), infection in 17 (11%), and other indications in 8 (5%). Concomitant medication use included 48 patients taking β-blockers, 8 patients taking verapamil, and 1 patient taking cimetidine. Review of past medical history indicated no patients with significant congestive heart failure or chronic liver disease. The mean length of FB was 33.5±18.9 minutes (range, 5 to 100 min). Bronchoalveolar lavage was performed in 64% of patients, transbronchial biopsy in 43%, transbronchial fine needle aspirate in 30%, cytology brushing in 25%, endobronchial biopsy in 18%, airway survey only in 11%, and other procedures in 3%. Mild symptoms were reported in 66.2% of all patients (85.3%—euphoria, 11.8%—dizziness, 1%—headache, 1%—drowsiness) and were more common in females (72.1%) than males (62.4%). No patients had cardiac arrhythmias, seizures, or respiratory failure attributable to lidocaine toxicity.

Total lidocaine dose, mean serum lidocaine levels, and mean blood MetHb levels for the overall group are shown in Table 1. The mean lidocaine dose was 1.17±0.20 g (range, 0.80 to 1.60 g). When adjusted for body weight, the mean lidocaine dose was 15.4±4.5 mg/kg (range, 7.1 to 32.5 mg/kg). The mean length of time until blood was drawn for lidocaine and MetHb levels was 51.1±11.8 minutes (range, 23 to 135 min). Mean serum lidocaine levels were 1.55±0.67 μg/mL with peak level of 5.1 μg/mL. Only 1 patient had a serum lidocaine level greater than 5 μg/mL. Mean blood MetHb levels were 0.69±0.26 μg/mL (range, 0.1 to 1.9 μg/mL). The normal range for our laboratory is 0.4 to 1.2 μg/mL; only 3 patients had a MetHb level greater than 1.2 μg/mL.

TABLE 1

TABLE 1

A further analysis of the values listed above was first completed by sex as shown in Table 1. There is a significant difference in lidocaine dose only by body weight, 14.3±3.8 mg/kg for males and 16.9±4.9 mg/kg for females with a P=0.0003. There were no differences in serum lidocaine or blood MetHb levels demonstrated. Comparison of lidocaine levels by indication for FB is shown in Table 2. Shorter FB procedures such as evaluation for infectious etiologies or airway survey for hemoptysis in which there is less manipulation of the airway did show a significant difference (P=0.027) in total lidocaine dose. This was not significant when adjusted for body weight or by lidocaine or MetHb levels. Similar findings are shown in Table 3 where comparisons were made on the basis of age group. There is less overall lidocaine used in older patients (P=0.029), but by body weight, there is no difference shown. No significant differences are shown in either lidocaine or MetHb levels. Patients with mild symptoms (n=102) versus no symptoms (n=52) showed no differences in lidocaine levels (1.53±0.58 μg/mL vs. 1.56±0.82 μg/mL, P=0.33) or MetHb levels (0.71±0.24 μg/mL vs. 0.66±0.30 μg/mL, P=0.79). β-blocker use (n=48) versus no β-blocker use (n=106) also showed no significant differences in lidocaine levels (1.58±0.81 μg/mL vs. 1.53±0.59 μg/mL, P=0.65) or MetHb levels (0.65±0.30 μg/mL vs. 0.71±0.24 μg/mL, P=0.19).

TABLE 2

TABLE 2

TABLE 3

TABLE 3

Back to Top | Article Outline

DISCUSSION

This is the largest study to date that assesses blood levels of lidocaine and the potential toxicity of high dose topical lidocaine in FB, although many numerous studies using smaller overall doses previously indicated the relative safety of lidocaine. Concern has been elucidated about the potential toxicities of lidocaine absorption during FB to include seizures, cardiac arrhythmias, respiratory arrest, and methemoglobinemia. These potential complications are more concerning for the elderly and patients with decreased hepatic clearance.11 This study has demonstrated that the routine use of high dose (>12 mg/kg) lidocaine in FB does not cause high serum lidocaine or blood MetHb levels, and does not predispose patients to complications from lidocaine toxicity. Lidocaine doses were significantly higher in females when adjusted for weight, but were not higher when comparing age or indication for FB.

Initial guidelines for lidocaine dosing in healthy asthmatics undergoing FB published by the NIH in 1985 recommended no more than 400-mg cumulative dose of lidocaine; no reference for this recommendation was cited.2 The updated guidelines on FB in asthmatics from an NIH workshop in 1991 simply stated the lowest topical anesthetic dose possible should be used.3 Despite these published guidelines, apprehension was justifiably raised in 1996 when a 19-year-old healthy volunteer died from lidocaine toxicity after undergoing a research FB.12 When the BTS published guidelines for FB in 2001, their recommendations were based primarily on 2 studies.5 One study of 48 asthmatics undergoing research FB demonstrated safety with a mean dose of 8.2 mg/kg of lidocaine as the upper limit of normal for these patients.4 Another smaller study by Milman et al13 of 16 patients undergoing FB recommended a maximum dosage of 6 to 7 mg/kg. Even current textbooks on FB do not stipulate a maximum dose of lidocaine despite the numerous published reports and guidelines.14

Despite the few references used by the BTS to develop their FB guidelines, the current medical literature contains a substantial collection of studies evaluating serum lidocaine levels during FB. A list of the 20 studies with lidocaine dosing and serum lidocaine levels is shown in Table 4.4,6–8,15–27 Two of these studies compared different dosages of lidocaine and 4 studies evaluated lidocaine in different patient populations (elderly vs. young, spraying vs. ultrasonic nebulization, upper vs. lower respiratory tract, presence of hepatic metastases).6,7,9,11,19,23 These studies included a total of 457 patients whose mean age was 47.4±23.7 years (not reported in 9 studies). The mean total dose of lidocaine was 488±463 mg (11 studies) or equivalent of 7.0 mg/kg in a 70 kg person. The mean lidocaine dose (reported as adjusted for weight) was 9.7±5.0 mg/kg (8 studies). Only 6 studies gave a lidocaine dose greater than 8.2 mg/kg or total dose greater than 600 mg. None of the studies reported an average peak lidocaine level >5.0 mg/kg, whereas only 3 of the 21 studies reported a maximum lidocaine level >5.0 mg/kg. This cumulative data of nearly 500 patients do not suggest a trend towards lidocaine toxicity with higher lidocaine levels.

TABLE 4

TABLE 4

Several studies have demonstrated the safety of higher doses of lidocaine during FB. In the earliest study in 1979, 12 FB patients received an average of 600 mg of topical lidocaine. The maximum lidocaine level was found to be 3.79 μg/mL in a patient with hepatic metastases who only received 420 mg topical lidocaine.18 A follow-up study in 1982 by Efthimiou et al20 of 41 FB patients used a similar mean lidocaine dose (9.3±0.5 mg/kg); mean peak levels were 2.9±0.5 μg/mL and 2 patients had a lidocaine level >5 μg/mL with no complications. Ameer et al6 compared an elderly group of 14 patients (mean age of 67 y) with a young group of 5 patients (mean age of 42 y). Both groups received total lidocaine doses of nearly 1200 mg without significant toxicity. No difference in mean or peak serum lidocaine was found between groups. As part of a study evaluating the effect of lidocaine on endobronchial cultures, Berger et al24 studied 8 patients who received an average total lidocaine dose greater than 2000 mg. The mean serum level was 2.7 μg/mL and the peak level in 1 patient was 5.5 μg/mL; no toxicity was reported. In 1997, Gjonaj et al7 evaluated 8 mg/kg versus 4 mg/kg of nebulized 2% lidocaine in a pediatric population and found no evidence of toxicity. The total lidocaine dose for the high dose group was 10.13±1.26 mg/kg with mean serum lidocaine levels of 1.17±0.54 μg/mL and peak levels of 2.27 μg/mL. The most recent studies by Loukides et al26 (mean lidocaine dose of 622±20 mg) and Sucena et al8 (mean lidocaine dose of 11.6±3.1 mg/kg) also found no toxicities with these doses. Notably, 5 of 30 patients studied by Sucena et al8 had serum levels greater than 5 μg/mL but no clinical toxicity.

Although elevated MetHb levels are another potential concern with the use of higher lidocaine doses, there is scant information supporting this as a significant clinical issue. The 1974 FB survey only noted symptoms related to methemoglobinemia in a single patient who received tetracaine.1 Karim et al28 reported 3 patients and received topical lidocaine who developed clinical evidence of methemoglobinemia; 1 patient was undergoing FB and was taking trimethoprim-sulfamethoxazole. Most methemoglobinemia cases have been in association with benzocaine used in combination with lidocaine or as the sole topical anesthetic.29–32 A study of intravenous lidocaine in 40 patients with arrhythmias also failed to show clinically significant elevated MetHb levels.33 Our cohort had 3 patients with MetHb levels slightly above normal but none were clinically significant.

There is sufficient prospective evidence from this study that higher doses of topical lidocaine for airway anesthesia during FB are well tolerated and safe in the majority of patients. We did not demonstrate a higher level of complications owing to lidocaine toxicity despite a mean dose nearly twice the BTS guidelines. Likewise, there was no evidence of higher serum lidocaine or blood MetHb levels owing to these high dose lidocaine doses. More importantly, the size of this study population confirms the safety of topical lidocaine as an adjunct in providing a comfortable and well-tolerated FB.

Back to Top | Article Outline

REFERENCES

1. Credle WF, Smiddy JF, Elliot RC. Complications of fiberoptic bronchoscopy. Am Rev Respir Dis. 1974;109:67–72.
2. National Institutes of Health workshop summary. Summary and recommendations of a workshop on the investigative use of fiberoptic bronchoscopy and bronchoalveolar lavage in individuals with asthma. J Allergy Clin Immunol. 1985;76:145–147.
3. Anonymous. Workshop summary and guidelines: investigative use of bronchoscopy, lavage, and bronchial biopsies in asthma and other airway diseases. J Allergy Clin Immunol. 1991;88:808–814.
4. Langmack EL, Martin RJ, Pak J, et al. Serum lidocaine concentrations in asthmatics undergoing research bronchoscopy. Chest. 2000;117:1055–1060.
5. British Thoracic Society Bronchoscopy Guidelines Committee. British Thoracic Society guidelines on diagnostic flexible bronchoscopy. Thorax. 2001;56(suppl I):i1–i21.
6. Ameer B, Burlingame MB, Harman EM. Systemic absorption of topical lidocaine in elderly and young adults undergoing bronchoscopy. Pharmacotherapy. 1989;9:74–81.
7. Gjonaj ST, Lowenthal DB, Dozor AJ. Nebulized lidocaine administered to infants and children undergoing flexible bronchoscopy. Chest. 1997;112:1665–1669.
8. Sucena M, Cachapuz I, Lombardia E, et al. Plasma concentration of lidocaine during bronchoscopy. Rev Port Pneumol. 2004;10:287–296.
9. Sutherland AD, Santamaria JD, Nana A. Patient comfort and plasma lignocaine concentrations during fibreoptic bronchoscopy. Anaesth Intensive Care. 1985;13:370–374.
10. Abernethy DR, Greenblatt DJ. Impairment of lidocaine clearance in elderly male subjects. J Cardiovasc Pharmacol. 1983;5:1093–1096.
11. Smith MJ, Dhillon DP, Hayler AM, et al. Is fibreoptic bronchoscopy in patients with lung cancer and hepatic metastases potentially dangerous? Br J Dis Chest. 1985;79:368–373.
12. Day RO, Chalmers DR, Williams KM, et al. The death of a healthy volunteer in a human research project: implications for Australian clinical research. Med J Aust. 1998;168:449–451.
13. Milman N, Laub M, Munch EP, et al. Serum concentrations of lignocaine and its metabolite monoethylglycinexylidide during fibre-optic bronchoscopy in local anaesthesia. Respir Med. 1998;92:40–43.
14. Rossberg MI, Toung TJK. Anesthesia for flexible fiberoptic bronchoscopy. In: Wang K, Mehta AC, Turner JF Jr, eds. Flexible Bronchoscopy. 2nd ed. Malden, MA: Blackwell Science; 2004:34–59.
15. Patterson JR, Blaschke TF, Hunt KK, et al. Lidocaine blood concentrations during fiberoptic bronchoscopy. Am Rev Respir Dis. 1975;112:53–57.
16. Karvonen S, Jokinen K, Karvonen P, et al. Arterial and venous blood lidocaine concentrations after local anaesthesia of the respiratory tract using an ultrasonic nebulizer. Acta Anaesthesiol Scand. 1976;20:156–159.
17. Boye NP, Bredesen JE. Plasma concentrations of lidocaine during inhalation anaesthesia for fiberoptic bronchoscopy. Scand J Respir Dis. 1979;60:105–108.
18. Le Lorier J, Larochelle P, Bolduc P, et al. Lidocaine plasma concentrations during and after endoscopic procedures. Int J Clin Pharmacol Biopharm. 1979;17:53–55.
19. Korttila K, Tarkkanen J, Tarkkanen L. Comparison of laryngotracheal and ultrasonic nebulizer administration of lidocaine in local anaesthesia for bronchoscopy. Acta Anaesthesiol Scand. 1981;25:161–165.
20. Efthimiou J, Higenbottam T, Holt D, et al. Plasma concentrations of lignocaine during fibreoptic bronchoscopy. Thorax. 1982;37:68–71.
21. Jones DA, McBurney A, Stanley PJ, et al. Plasma concentrations of lignocaine and its metabolites during fibreoptic bronchoscopy. Br J Anaesth. 1982;54:853–857.
22. Gomez F, Barrueco M, Lanao JM, et al. Serum lidocaine levels in patients undergoing fibrobronchoscopy. Therap Drug Monit. 1983;5:201–203.
23. McBurney A, Jones DA, Stanley PJ, et al. Absorption of lignocaine and bupivacaine from the respiratory tract during fibreoptic bronchoscopy. Br J Clin Pharmacol. 1984;17:61–66.
24. Berger R, McConnell JW, Phillips B, et al. Safety and efficacy of using high-dose topical and nebulized anesthesia to obtain endobronchial cultures. Chest. 1989;95:299–303.
25. Amitai Y, Zylber-Katz E, Avital A, et al. Serum lidocaine concentrations in children during bronchoscopy with topical anesthesia. Chest. 1990;98:1370–1373.
26. Loukides S, Katsoulis K, Tsarpalis K, et al. Serum concentrations of lignocaine before, during and after fiberoptic bronchoscopy. Respiration. 2000;67:13–17.
27. Mainland PA, Kong AS, Chung DC, et al. Absorption of lidocaine during aspiration anesthesia of the airway. J Clin Anesth. 2001;13:440–446.
28. Karim A, Ahmed S, Siddiqui R, et al. Methemoglobinemia complicating topical lidocaine used during endoscopic procedures. Am J Med. 2001;111:150–153.
29. Kern K, Langevin PB. Methemoglobinemia after topical anesthesia with lidocaine and benzocaine for a difficult intubation. J Clin Anesth. 2000;12:167–172.
30. O'Donohue WJ Jr, Moss LM, Angelillo VA. Acute methemoglobinemia induced by topical benzocaine and lidocaine. Arch Intern Med. 1980;140:1508–1509.
31. Kuschner WG, Chitkara RK, Canfield J Jr, et al. Benzocaine-associated methemoglobinemia following bronchoscopy in a healthy research participant. Respir Care. 2000;45:953–956.
32. Rodriguez LF, Smolik LM, Zbehlik AJ. Benzocaine-induced methemoglobinemia: report of a severe reaction and review of the literature. Ann Pharmacother. 1994;28:643–649.
33. Weiss LD, Generalovinch T, Heller MB, et al. Methemoglobin levels following intravenous lidocaine administration. Ann Emerg Med. 1987;16:323–325.
Keywords:

lidocaine; flexible bronchoscopy; toxicity; methemoglobin

© 2008 Lippincott Williams & Wilkins, Inc.